Africa: Genuine use and reputation in South Africa

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Africa: Genuine use and reputation in South Africa

South Africa's Supreme Court of Appeal recently handed down two important judgments. One dealt with genuine use, the other with reputation.

In Westminster Tobacco Co v Philip Morris Products SA (March 16 2017), the issue was whether use made by Westminster (part of BAT) of its registered trade mark Parliament was genuine, and enough to save the registration from attack for non-use. The authorities tell us that use must not be "merely token, serving solely to preserve the rights conferred by the mark". They say that the intention behind the use must be "to maintain or create a share in the market for the goods or services protected by the mark".

The court accepted that BAT did put the mark Parliament in use with a view to protecting the registration. But there was more to it than that – the company was also keen to test a cigarette that would compete with low-cost brands that were eating into BAT's market share. Even though BAT's launch of the low-cost cigarette was not a great success and did not last very long, this did not stop the use from being genuine. These are probably the most important words in the judgment:

Genuineness is to be contrasted with use that is merely token, but the line is a fine one, because the use may be minimal… it may in part be prompted by the fear of removal from the register and be directed at protecting the proprietor's trade generally or preventing the mark from falling into the hands of a competitor.

Herbal Zone v Infitech Technologies (March 10 2017) was a passing off case involving an unregistered mark. In this case an aphrodisiac product that was manufactured by a company in Malaysia was imported into, and sold in, South Africa by a South African company. Who owned the reputation in the mark? The court said that it clearly did not belong to the importer, who had disclaimed rights to the IP in its agreement: "In the face of that disavowal it is difficult to see on what possible basis Infitech could nonetheless acquire the very rights it agreed did not belong to it."

But the court did accept the principle that an importer/ distributor can acquire a reputation in the goods that it sells. But only where it adds something to the mark or get-up "to identify itself as the source of the goods".

Wayne Meiring


Spoor & Fisher JerseyAfrica House, Castle StreetSt Helier, Jersey JE4 9TWChannel IslandsTel: +44 1534 838000Fax: +44 1534 838001

info@spoor.co.ukwww.spoor.com

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article